Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.

D. F. Hayes; T. M. Walker; B. Singh; E. S. Vitetta; J. W. Uhr; S. Gross; C. Rao; G. V. Doyle; L. W. Terstappen

doi:10.3892/ijo.21.5.1111

Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.

D. F. Hayes, T. M. Walker, B. Singh, E. S. Vitetta, J. W. Uhr, S. Gross, C. Rao, G. V. Doyle, L. W. Terstappen

Research output: Contribution to journal › Article › peer-review

149 Scopus citations

Abstract

Nineteen breast cancer patients with measurable metastatic disease who were starting an initial or new line of therapy were evaluated for circulating epithelial cells (CECs) a minimum of 4 times over the course of treatment. In 7 of the 10 CEC+ patients, HER-2 expression was detected on the CECs. CECs expressing HER-2 varied among patients and in serial samples from the same patient including a shift from HER-2- to HER-2+ CECs. These results demonstrate that it is possible to quantify receptors essential for rationally designed therapy using CECs and that reliance on the immunophenotype of the primary tumor can be misleading.

Original language	English (US)
Pages (from-to)	1111-1117
Number of pages	7
Journal	International journal of oncology
Volume	21
Issue number	5
DOIs	https://doi.org/10.3892/ijo.21.5.1111
State	Published - Nov 2002

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3892/ijo.21.5.1111

Cite this

@article{9aab58e5d9fd462a962f06b8ef87df0d,

title = "Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.",

abstract = "Nineteen breast cancer patients with measurable metastatic disease who were starting an initial or new line of therapy were evaluated for circulating epithelial cells (CECs) a minimum of 4 times over the course of treatment. In 7 of the 10 CEC+ patients, HER-2 expression was detected on the CECs. CECs expressing HER-2 varied among patients and in serial samples from the same patient including a shift from HER-2- to HER-2+ CECs. These results demonstrate that it is possible to quantify receptors essential for rationally designed therapy using CECs and that reliance on the immunophenotype of the primary tumor can be misleading.",

author = "Hayes, {D. F.} and Walker, {T. M.} and B. Singh and Vitetta, {E. S.} and Uhr, {J. W.} and S. Gross and C. Rao and Doyle, {G. V.} and Terstappen, {L. W.}",

year = "2002",

month = nov,

doi = "10.3892/ijo.21.5.1111",

language = "English (US)",

volume = "21",

pages = "1111--1117",

journal = "International journal of oncology",

issn = "1019-6439",

publisher = "Spandidos Publications",

number = "5",

}

TY - JOUR

T1 - Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.

AU - Hayes, D. F.

AU - Walker, T. M.

AU - Singh, B.

AU - Vitetta, E. S.

AU - Uhr, J. W.

AU - Gross, S.

AU - Rao, C.

AU - Doyle, G. V.

AU - Terstappen, L. W.

PY - 2002/11

Y1 - 2002/11

N2 - Nineteen breast cancer patients with measurable metastatic disease who were starting an initial or new line of therapy were evaluated for circulating epithelial cells (CECs) a minimum of 4 times over the course of treatment. In 7 of the 10 CEC+ patients, HER-2 expression was detected on the CECs. CECs expressing HER-2 varied among patients and in serial samples from the same patient including a shift from HER-2- to HER-2+ CECs. These results demonstrate that it is possible to quantify receptors essential for rationally designed therapy using CECs and that reliance on the immunophenotype of the primary tumor can be misleading.

AB - Nineteen breast cancer patients with measurable metastatic disease who were starting an initial or new line of therapy were evaluated for circulating epithelial cells (CECs) a minimum of 4 times over the course of treatment. In 7 of the 10 CEC+ patients, HER-2 expression was detected on the CECs. CECs expressing HER-2 varied among patients and in serial samples from the same patient including a shift from HER-2- to HER-2+ CECs. These results demonstrate that it is possible to quantify receptors essential for rationally designed therapy using CECs and that reliance on the immunophenotype of the primary tumor can be misleading.

UR - http://www.scopus.com/inward/record.url?scp=0036834995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036834995&partnerID=8YFLogxK

U2 - 10.3892/ijo.21.5.1111

DO - 10.3892/ijo.21.5.1111

M3 - Article

C2 - 12370762

AN - SCOPUS:0036834995

SN - 1019-6439

VL - 21

SP - 1111

EP - 1117

JO - International journal of oncology

JF - International journal of oncology

IS - 5

ER -

Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this